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ABSTRACT High cryptococcal antigen (CrAg) titers in blood are associated with
subclinical meningitis and mortality in CrAg-positive individuals with advanced
HIV disease (AHD). We evaluated a novel semiquantitative lateral flow assay
(LFA), CryptoPS, that may be able to identify individuals with high CrAg titers in
a cohort of AHD patients undergoing CrAg screening. In a prospective cohort of
patients with AHD (CD4 cell count, 200/l) receiving CD4 count testing, whole
blood was tested for CrAg by CryptoPS and the IMMY LFA; the two assays were
conducted by two different operators, each blind to the results of the other as-
say. The sensitivity, specificity, positive predictive value (PPV), and negative pre-
dictive value (NPV) of CryptoPS were assessed against the IMMY LFA as a refer-
ence. CryptoPS low-titer (T1 band) and high-titer (T2 band) results were
compared with IMMY LFA titers obtained through serial dilution. A total of 916
specimens were tested. The sensitivity of the CryptoPS assay was 61.0% (25/41)
(95% confidence interval [95% CI], 44.5 to 75.8%), its specificity was 96.6% (845/
875) (95% CI, 95.1 to 97.7%), its PPV was 45.5% (95% CI, 32.0 to 59.4%), and its
NPV was 98.1% (95% CI, 97.0 to 98.9%). All (16/16) CryptoPS false-negative re-
sults were obtained for samples with IMMY titers of 1:160. Of 29 patients (30
specimens) who tested positive by CryptoPS but negative by the IMMY LFA,
none developed cryptococcal meningitis over 3 months of follow-up without flu-
conazole. Median CrAg titers were 1:20 (interquartile range [IQR], 0 to 1:160) in
CryptoPS T1-positive samples and 1:2,560 (IQR, 1:1,280 to 1:10,240) in T2-positive
samples. We conclude that the diagnostic accuracy of the CryptoPS assay was
suboptimal in the context of CrAg screening, with poor sensitivity at low CrAg ti-
ters. However, the CryptoPS assay reliably detected individuals with high titers,
which are associated with poor outcomes.
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Cryptococcal meningitis (CM) remains a major cause of mortality in persons livingwith HIV (PLWH), causing an estimated 15% of HIV-related deaths worldwide (1). In
individuals with advanced HIV disease (AHD), detection of cryptococcal antigen (CrAg)
in the blood has been shown to precede the development of CM (2, 3). CrAg screening
of patients with AHD starting antiretroviral therapy (ART), with targeted preemptive
fluconazole for CrAg-positive patients, has been shown to reduce incident CM and
all-cause mortality (4) and is recommended by the World Health Organization (WHO)
for those starting or reinitiating ART with a CD4 T-cell count of 200/l (5).
Preemptive fluconazole therapy for CrAg-positive individuals reduces, but does not
completely eliminate, excess mortality (6); as many as one-third of asymptomatic
CrAg-positive patients with AHD have disseminated central nervous system (CNS)
disease and may require more-potent antifungal regimens for effective treatment (5–7).
Higher CrAg titers (1:160) are associated with an increased risk of CNS disease and
death in CrAg-positive individuals (7–9). Titers can be assessed through serial dilution
using commercial assays, but this requires extended labor and additional costs, making
it impractical in resource-limited settings. Semiquantitative CrAg assays may provide a
simpler means of stratifying risk for CrAg-positive patients with AHD and guiding
differentiated treatment strategies.
CryptoPS (Biosynex, Strasbourg, France) is a semiquantitative immunochromato-
graphic assay that detects all Cryptococcus neoformans/Cryptococcus gattii serotypes
and provides results within 10 min. The assay has a control band, a qualitative T1 band
for CrAg positivity, and a semiquantitative T2 band indicating a “high” CrAg titer (Fig.
1). Just two limited diagnostic evaluations have been reported to date (10, 11). In a
small study of patients with CD4 cell counts of 100/l in Cameroon, CryptoPS had
good agreement with a commercial lateral flow assay (LFA) (IMMY Diagnostics, Norman,
OK, USA) and an enzyme immunoassay (EIA) (Premier CrAg; Meridian Bioscience, Inc.,
Newtown, OH, USA), with a median reciprocal EIA titer of 1:160 correlating with T2
band positivity, although the sample size, which included just 14 serum CrAg-positive
patients, limited estimates of precision (10). A second study testing 99 archived serum
samples selected from a cohort of HIV-positive Ugandans undergoing CrAg screening
reported similar findings, with reasonable agreement between the CryptoPS and IMMY
LFA and median CrAg titers of 1:320 for those with T2 band positivity (11); however, this
study was also limited by a small sample size. CryptoPS was not tested on whole-blood
samples, likely to be beneficial for point-of-care testing, in either study, and the assay
has not been evaluated prospectively and under routine care conditions.
We investigated the diagnostic performance of the CryptoPS assay in a prospective
CrAg screening cohort in Botswana, evaluating test accuracy (sensitivity, specificity,
positive predictive value [PPV], and negative predictive value [NPV]) against a validated
reference standard. To determine titer cutoffs for the CryptoPS T2 band (high titers), we
compared CryptoPS readings with IMMY CrAg titer results by serial dilution.
MATERIALS AND METHODS
From January 2018 to January 2019, we performed real-time CrAg testing on EDTA whole-blood
samples from a sequential cohort of individuals with CD4 cell counts of 200/l undergoing routine
reflex CrAg screening at the Botswana-Harvard HIV Reference Laboratory (BHHRL). The BHHRL performs
all CD4 testing for 27 ART clinics and a central referral hospital located around Gaborone. The full cohort
has been described in detail elsewhere (12); briefly, CD4 T-cell count testing was performed using flow
cytometry (FACSCalibur; Becton, Dickinson and Company, Franklin Lakes, NJ, USA); residual EDTA blood
from sequential samples with CD4 cell counts of 200/l was screened for CrAg in real time using the
IMMY LFA (IMMY, Norman, OK, USA) as a validated reference standard (13, 14). CryptoPS testing was
performed by a second trained operator blind to the IMMY LFA results. Results were interpreted by visual
reading as negative (only the control band was visualized), T1 band positive (with the control and T1
bands visualized by the operator), or T2 band positive (control, T1, and T2 bands visualized), as per
manufacturer’s instructions (Fig. 1).
Since the CryptoPS is not registered for diagnostic use in Botswana, all clinical management decisions
were based on IMMY LFA results. IMMY LFA-positive patients were managed according to the Botswana
National HIV Management Guidelines (15). Individuals who tested positive by CryptoPS but negative by
the IMMY LFA were contacted by the study team for retesting with the IMMY LFA and were monitored
for 3 months in order to be evaluated for the development of incident CM, but they did not receive
antifungal therapy unless the repeat IMMY LFA results were positive. Three-month outcomes in these
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individuals with positive CryptoPS results but negative IMMY LFA results were assessed through
telephone contact, review of a national electronic medical records system, review of clinical notes, or
further contact with clinical providers as needed.
At the end of the study period, IMMY LFA titers were determined by serial dilution of plasma samples
stored at 80°C. To enable further validation of the CryptoPS semiquantitative results, we used both
CryptoPS and the IMMY LFA to test an additional collection of 141 archived known CrAg-positive plasma
samples from (i) patients in a CrAg screening cohort from 2015 to 2016 (8) and (ii) patients with CM
enrolled in a completed phase II clinical trial evaluating induction therapies (16). All CrAg testing was
performed by laboratory scientists blind to previous testing results.
Finally, to better characterize samples with discordant CryptoPS and IMMY LFA test results, we
retested all discordant samples with Meridian’s CrAg EIA (Meridian Bioscience, Cincinnati, OH) and
IMMY’s EIA (IMMY, Norman, OK) at the National Institute for Communicable Diseases (NICD) in Johan-
nesburg, South Africa. This study was approved by institutional review boards at the Botswana Ministry
of Health and Wellness, the University of Botswana, Princess Marina Hospital, and the University of
Pennsylvania.
Statistical analysis. In the prospective CrAg screening cohort, we determined the sensitivity,
specificity, PPV, and NPV of the CryptoPS assay with 95% confidence intervals (95% CI) using the IMMY
LFA assay as a reference standard. Using all CrAg-positive samples from the prospective screening cohort,
plus the additional archived CrAg-positive samples, we evaluated the median and interquartile range
(IQR) of dilutional IMMY LFA CrAg titer values in samples with CryptoPS that were T1 band and T2 band
positive, and we displayed the results graphically.
Laboratory findings, including the results of cryptococcal EIA testing, were described for samples with
discordant CryptoPS-LFA results, and clinical outcomes were reported for individuals with negative IMMY
LFA but positive CryptoPS results. Analyses were performed using Stata, version 16 (College Station, TX,
USA).
RESULTS
Sensitivity and specificity of CryptoPS in a sequential cohort of individuals
with CD4 cell counts of <200/l. A total of 916 sequential blood samples from 870
unique patients (of whom 46 had repeat CD4 testing and reflex CrAg screening [Table
1]) were tested with the IMMY LFA and the CryptoPS CrAg assay; the median age was
39 years (interquartile range [IQR], 33 to 46 years), 58.4% (507/868; 2 missing data) were
male, and the median CD4 cell count was 142/l (IQR, 85 to 174 cells/l). By use of
IMMY LFA testing, 41 of the 916 samples were CrAg positive (4.5% [95% confidence
interval {CI}, 3.2 to 6.0%]) with a median CrAg titer of 1:80 (IQR, 1:20 to 1:960). Using the
IMMY LFA as the reference standard, the sensitivity of CryptoPS was 61.0% (95% CI, 44.5
to 75.8%), and its specificity was 96.6% (95% CI, 95.1 to 97.7%), yielding a PPV of 45.5%
(95% CI, 32.0 to 59.4%) and an NPV of 98.1% (95% CI, 97.0 to 98.9%) in our cohort (Table
2).
The CryptoPS assay was positive in 55/916 (6.0% [95% CI, 4.6 to 7.7%]) of samples;
25/55 (45.5%) were IMMY LFA positive and were classified as “true positives” (18 T1
FIG 1 CryptoPS semiquantitative assay. Twenty microliters of a blood specimen is added to the collection
well of the cassette, followed by 3 drops of sample diluent, with the result read at 10 min. (A) Negative
result (control band positive); (B) :Low-titer positive result (T1 and control bands positive); (C) High-titer
positive result (T1, T2, and control bands positive). Patient initials and study identification codes written
on the bottoms of the test strips have been concealed to ensure the anonymity of the research
participants.
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band and 7 T2 band). The remaining 30/55 (54.5%) CryptoPS-positive samples were
IMMY LFA negative and were classified as “false positives” (29 T1 band and 1 T2 band).
On confirmatory testing, all 30 of the CryptoPS false-positive results were Meridian EIA
negative, and 29/30 were IMMY EIA negative, with one low-level positive (Fig. 2a).
Sixteen samples were IMMY LFA positive but CryptoPS negative and were classified as
“false negatives”; all had IMMY LFA CrAg titers of 1:160, and 13 of the 16 had titers
of 1:40. Three of the 16 were LFA positive only at the lowest dilution tested (1:2) and
negative on the IMMY EIA (Fig. 2b).
Detailed characteristics of the patients with the 30 false-positive CryptoPS results are
shown in Table 3. The 30 “false-positive” CryptoPS samples were from 29 patients (one
had two tests); 79% (23/29) received repeat IMMY LFA testing, of whom 100% (23/23)
were CrAg negative. Most (97% [28/29]) were on ART at the time of CrAg screening, and
none received preemptive fluconazole. None (0/29) were diagnosed with cryptococcal
meningitis in the 3 months following CD4 testing and reflex CrAg screening, and 28/29
were alive at the completion of follow-up. One patient died 5 days after the date of CD4
testing after presenting to hospital with a clinical diagnosis of a lower respiratory tract
infection; no central nervous system infection was suspected, and the patient did not
receive a lumbar puncture as part of his diagnostic evaluation. The patient’s CryptoPS
result was T1 band positive, with negative IMMY LFA, IMMY EIA, and Meridian EIA
results.
TABLE 1 Baseline characteristics of study participantsa
Group and variable Valueb
Sequential cohort of individuals with CD4 cell counts of 200/l screened
for CrAg (916 samples from 870 individuals)c
Age (yr) (IQR)d 39 (33–46)
% maled 58 (507/868e)
CD4 cell count/l (IQR)f 142 (86–174)
% (no.) positive for cryptococcal antigenemiaf,g 4.5 (41)
% on ARTf 75 (691/916)
% with prior cryptococcal meningitisd 1 (13/870)
Additional individuals included in titer validation cohort
(all CrAg positive [n  141])g
Age (yr) (IQR) 38 (32–44)
% male 58 (81/139e)
CD4 cell count/l (IQR) 31 (12–63)
% (no.) positive for cryptococcal antigenemiag 100 (141)
aART, antiretroviral therapy; CrAg, cryptococcal antigen; IQR, interquartile range; LFA, lateral flow assay.
bExcept where otherwise indicated, values are given as the median (IQR) or as a percentage (number of
individuals with the characteristic/total number).
cA total of 916 samples from 870 unique patients were tested; 46 individuals had repeat samples.
dAge, sex, and prior cryptococcal meningitis data are reported for the 870 individuals in the CrAg screening
cohort at the time of their first CrAg test.
eData were missing for two individuals.
fCD4 cell counts, IMMY CrAg LFA results, and ART status at the time of testing (some patients were tested
twice during screening period) are shown; of 226 patients not on ART at date of CD4 testing, 17% (39) had
defaulted from ART and 83% (187) had no history of ART use.
gCrAg results obtained using the IMMY CrAg lateral flow assay.




No. of samples with
the following result
by the IMMY LFA:
Total no. of samples
with the indicated
result by CryptoPS
CryptoPS accuracy (% [95% CI])
Positive Negative Sensitivity Specificity PPV NPV
Positive 25 30 55
Negative 16 845 861
Total 41 875 916 61.0 (44.5–75.8) 96.6 (95.1–97.7) 45.5 (32.0–59.4) 98.1 (97.0–98.9)
aTests were performed on whole-blood samples. PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; LFA, lateral flow assay.
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Given the relatively low sensitivity and specificity of the CryptoPS assay on EDTA
whole blood, we repeated CryptoPS testing on frozen plasma samples after study
completion (with operators blind to the previous results), which yielded results very
similar to those of real-time whole blood testing for these specimens (see Table S1 in
the supplemental material). We also repeated the analysis restricted to individuals with
CD4 cell counts of 100/l; in this subgroup, the sensitivity of CryptoPS was 83.3%
(95% CI, 58.6 to 96.4%), and its specificity was 96.5% (95% CI, 93.5 to 98.4%) (Table S2).
Relationship between CryptoPS bands and dilutional CrAg titers. When the
samples from the sequential CrAg screening cohort were combined with 141 archived
IMMY LFA CrAg-positive blood samples, 870 samples were CryptoPS negative, 102 were
T1 band positive, and 84 were T2 band positive (one CryptoPS T2-positive individual in
the sequential cohort did not have sufficient residual plasma for titration). The median
IMMY LFA titer of the T1 band-positive samples was 1:20 (IQR, LFA negative to 1:160).
The median titer of the CryptoPS T2 band-positive samples was 1:2,560 (IQR, 1:1,280 to
1:10,240); 79/84 (94%) T2-positive samples had titers of 1:160 (Fig. 3).
DISCUSSION
In this prospective evaluation of the novel semiquantitative CryptoPS CrAg LFA for
HIV-seropositive individuals with CD4 cell counts of 200/l who were undergoing
CrAg screening, we found suboptimal assay sensitivity of CryptoPS compared to an
established CrAg LFA (IMMY). The lower sensitivity of CryptoPS was exclusively due to
false-negative test results on blood samples with low CrAg titers; all samples with titers
of 1:160 were detected by the assay.
Our study adds to two small prior diagnostic validation studies of the CryptoPS
assay. A study of stored serum samples from Cameroon found a test sensitivity of 78%
(11/14) against the IMMY LFA (10). The median CD4 cell count of samples in this study
FIG 2 Discordant CryptoPS and IMMY LFA results. (A) CryptoPS “false-positive” results with secondary testing using
the IMMY EIA; 29/30 samples tested negative on the IMMY EIA at an optical density below the positive cutoff, and
1 sample tested positive at an optical density of 0.625. All samples tested negative using the Meridian EIA. (B)
CryptoPS “false-negative” results with IMMY LFA dilutional titer and IMMY EIA optical density; 16/16 samples had
an IMMY LFA titer of 1:160, and 3 tested negative on the IMMY EIA at an optical density below the positive cutoff,
all 3 were IMMY LFA positive only in undiluted samples, indicating very low titers.
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was lower than that in our cohort (44 cells/l versus 142 cells/l), likely resulting in a
higher median CrAg titer (1:160 versus 1:80) and contributing to slightly higher
observed sensitivity (12). A second study of 99 cryopreserved serum samples from a
Ugandan CrAg screening cohort found a CryptoPS assay sensitivity of 88% (50/57 [95%
CI, 76% to 95%]) and a specificity of 95% (40/42) (95% CI, 84% to 99%) against the IMMY
LFA; however, only 65% of samples with an IMMY LFA dilutional titer of 1:20 were
positive on the CryptoPS assay (11). Similarly, in our prospective evaluation, all (16/16)
false-negative whole-blood CryptoPS results were on samples with CrAg titers of
1:160, 13 of which (81%) had titers of 1:40. These patients may be at relatively low
risk for progression to meningitis in the absence of preemptive fluconazole, assuming
prompt initiation or continuation of effective ART (17).
While the CryptoPS assay had suboptimal overall sensitivity, the T2 band performed
well in discriminating samples that had high CrAg titers with greater risk of meningitis
and/or failure of preemptive fluconazole therapy (6), with 79/84 (94%) of T2 band-
positive samples from stored blood found to have titers of 1:160 by serial dilution.
The assay may have clinical utility in recognizing CrAg-positive patients who require
further diagnostic evaluation for meningitis and enhanced antifungal treatment, albeit
at the expense of missing a proportion of patients with lower CrAg titers who are still
likely to benefit from standard preemptive fluconazole treatment (18). To avoid missing
these individuals with lower titers, CryptoPS could be used as a second test, performed
after an initial IMMY LFA screen, to identify the highest-risk individuals with T2 bands
for enhanced care. The ease of use and interpretation of the CryptoPS tests may make
this an attractive strategy in some settings.
We found moderate specificity of the CryptoPS assay, in keeping with the previous
study from Uganda, but with greater estimated precision given our larger sample size
(11). We carefully followed the 29 patients with presumed false-positive CryptoPS
results (a positive CryptoPS result and a negative IMMY LFA result) for at least 3 months.
FIG 3 Comparison of CryptoPS titer results with dilutional titers obtained using the IMMY LFA. The violin plots show the distribution
of dilutional CrAg titers in CryptoPS-negative, T1 (low-titer), and T2 (high-titer) samples, comprising 916 prospectively screened
samples and 141 additional archived CrAg-positive plasma samples. Twenty-five CryptoPS-negative samples (16 from the prospective
cohort and 9 archived samples) were positive on IMMY testing, all at titers of 1:160. Twenty-nine CryptoPS T1-positive samples and
1 CryptoPS T2-positive sample were IMMY LFA negative. Median titers in the T1 and T2 groups with interquartile ranges are given.
Note that in the treatment trial from which some of the archived samples were taken, the maximum dilutional titer measured was
1:2,560; hence, some titers at this level may have been higher if further dilutions had been performed.
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All patients (23/29) with repeat IMMY LFA testing again tested negative; all were
negative with secondary testing using the Meridian EIA, and all but one with the IMMY
EIA. None developed meningitis despite receiving no antifungal treatment, supporting
the classification of these results as false positive. Further, nearly all these patients were
confirmed to be alive over follow-up; one patient died shortly after screening, but for
causes likely unrelated to cryptococcal disease. Given a relatively low prevalence of
cryptococcal antigenemia in patients with AHD (19), the positive predictive value of the
CryptoPS assay in the prospective cohort was below 50%, with more false-positive than
true-positive results.
Our study is subject to several limitations. First, Cryptococcus sp. isolates have
significant serotype diversity within Southern Africa, which may impact test sensitivity
(20, 21). Although the CryptoPS assay can detect all Cryptococcus neoformans/Crypto-
coccus gattii serotypes, different genotypic and phenotypic characteristics of local fungi
could potentially have impacted test performance. Second, although the IMMY LFA and
the CryptoPS test were read by trained laboratory operators blind to the results of the
other assay, we did not have two independent reviewers read the CryptoPS assay to
evaluate inter-rater reliability. However, we repeated CryptoPS testing on the same
stored plasma specimens with similar test results, and all IMMY LFA-positive samples
underwent further testing through serial dilution, confirming positive results, so the
findings are highly likely to be valid.
In summary, the CryptoPS assay provides rapid semiquantitative CrAg test results on
whole-blood specimens and good discrimination for high-titer results. Limitations in
sensitivity and specificity may limit the clinical use of this assay in cryptococcal
antigen-screening programs, which typically aim to detect individuals with relatively
low cryptococcal antigen burdens. These limitations may be less marked when one is
testing individuals with suspected cryptococcal meningitis, who have a higher pretest
probability of infection and higher blood CrAg titers.
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